Biogen Idec to present new drug data at ECTRIMS 2013

Biogen Idec has announced that it will be attending the forthcoming annual congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen.

During the conference from October 2nd to 5th 2013, the company will present 58 data sets from the company's multiple sclerosis (MS) clinical portfolio, including information on both approved and investigational products.

The firm will share the latest clinical findings on established therapies such as Tysabri, Tecfidera and Fampyra, as well as newer agents including Plegridy, Anti-Lingo-1 and daclizumab.

It will also take the opportunity to launch its new Multiple Sclerosis Registry Research Fellowship programme.

Dr Douglas Williams, executive vice-president for research and development at Biogen Idec, said: "We are excited to be presenting data on some promising candidates which have the potential to broaden the treatment spectrum for people living with this chronic, debilitating disease."

Earlier this month, the company announced a new partnership with Amicus Therapeutics, which will focus on the development of new therapies for Parkinson's disease.